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Abstract
Background: Recent studies showed that the non-adherence to the pharmacological therapy of patients affected by BPH-
associated LUTS increased the risk of clinical progression of BPH. We examined the patients adherence to pharmacological
therapy and its clinical consequences in men with BPH-associated LUTS looking at the differences between drug
classes comparing mono vs combination therapy.
Methods: A retrospective, population-based cohort study, using prescription administrative database and hospital
discharge codes from a total of 1.5 million Italian men. Patients ≥40 years, administered alpha-blockers (AB) and
5alpha-reductase inhibitors (5ARIs), alone or in combination (CT), for BPH-associated LUTS were analyzed. The 1–year
and long term adherence together with the analyses of hospitalization rates for BPH and BPH-related surgery were
examined using multivariable Cox proportional hazards regression model and Pearson chi square test.
Results: Patients exposed to at least 6 months of therapy had a 1-year overall adherence of 29 % (monotherapy AB
35 %, monotherapy 5ARI 18 %, CT 9 %). Patient adherence progressively declined to 15 %, 8 % and 3 % for AB, 5ARI, and
CT, respectively at the fifth year of follow up. Patients on CT had a higher discontinuation rate along all the follow-up
compared to those under monotherapy with ABs or 5ARIs (all p < 0.0001). Moreover, CT was associated with a reduced
risk of hospitalization for BPH-related surgery (HR 0.94; p < 0.0001) compared to AB monotherapy.
Conclusions: Adherence to pharmacological therapy of BPH-associated LUTS is low and varies depending on drugs
class. Patients under CT have a higher likelihood of discontinuing treatment for a number of reasons that should be
better investigated. Our study suggests that new strategies aiming to increase patient’s adherence to the prescribed
treatment are necessary in order to prevent BPH progression.
Keywords: Patient adherence, Drug therapy, Benign prostatic hyperplasia, Lower urinary tract symptoms, Alpha blockers,
5alfa reductase inhibitors, Administrative databases, Dutasteride, Finasteride, record-linkage analysis
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Background
Benign prostatic enlargement (BPE) is caused by a
very common histopathological condition in aging
men; benign prostatic hyperplasia (BPH). Clinical
manifestations of BPH include lower urinary tract
symptoms (LUTS), signs and sequelae of bladder out-
let obstruction caused by BPE [1]. The prevalence of
moderate-to-severe LUTS is high, increasing from
22 % among 50–59 year-old men to 45 % among
those in the seventh decade of life. However only 19 %
of men suffering from BPH-associated LUTS seek medical
treatment and only 10.2 % receive pharmacological treat-
ment [2–4].
Pharmacological therapy for BPH-associated LUTS aims
at improving the patient’s quality of life by relieving urin-
ary symptoms and to a certain extent, by preventing the
development of BPH-related complications. International
guidelines agree that patients with moderate-to-severe
LUTS are initially best managed with pharmacological
therapy [5, 6].
Five classes of drugs are usually prescribed for the
treatment of BPH-associated LUTS: alpha blockers (AB),
5-alpha reductase inhibitors (5ARI), phosphodiesterase-5
(PDE-5) inhibitors, antimuscarinics/beta3 agonists, and
phytotherapeutics. Combination therapy (CT) with ABs
and 5ARIs has been shown to be beneficial in terms of
symptom control and disease progression [7–9].
Although pharmacological treatment of BPH is
considered a success story among urologists, daily practice
suggests that several patient’s needs remain unmet.
Whether or not this is due to drug’s limitations, inappro-
priate patient management or low patient adherence to
drug therapy remains unclear[4,10, 11]. Drug prescription
trends and patterns for BPH-associated LUTS show a
wide variation amongst countries, this variation is attrib-
uted to geographical, societal and cultural differences, cost
of medications and different health policies.
A recent paper from our group showed that in “real
life” practice the adherence to long-term treatment for
BPH-associated LUTS significantly impacts BPH pro-
gression [12]. Data on adherence are of importance in
order to understand possible unmet needs, explore pa-
tient preferences and identify areas for intervention for
the health care systems [13]. In this specific issue, data
from other areas of medicine confirmed that multiple
medications (pills/day) could impact on patient adher-
ence, suggesting that a fixed dose combination (more
than a 2-pill therapy) can yield important improvements
in patient drug adherence [14].
The aim of this study is to evaluate the patient adher-
ence to pharmacological therapy for BPH-associated
LUTS, and to analyze the adherence among drug regi-
mens (CT vs monotherapy) together with long-term ef-
fects of drugs discontinuation.
Methods
A population-based cohort study was conducted using
record-linkage analysis of three databases: drug prescrip-
tions database, civil registry and hospital discharge re-
cords (HDR) (data on 6.5 million subjects across 22
local Italian Health Authorities).
All Italian citizens have access to health care services;
medical and pharmaceutical services are provided for
free or at a minimum charge as part of the National
Health Service (NHS).
The Italian national drug database includes the prescrip-
tions reimbursed by the Italian NHS; drugs are coded
according to the Anatomical Therapeutic Chemical (ATC)
Classification [15] and qualified with respect to dosage,
and the date of the first and subsequent prescriptions
from which data on adherence can be derived.
This cohort was linked with HDR which includes
information on primary diagnoses and up to 5 coexisting
conditions, performed procedures, dates of hospital ad-
mission and discharge. Diagnoses are classified accord-
ing to the International Classification of Diseases-Ninth
Revision, Clinical Modification (ICD9-CM) [16].
The Italian civil registry provides demographic
information.
This study’s methodology has been widely used to pro-
duce reliable epidemiological surveys [12,17, 18]. The
analysis was carried out in strict compliance with the na-
tional Italian regulations for the full protection of the
privacy rights of the subjects included in the databases.
According to the Italian law, no ethical approval is re-
quired to perform this type of analysis and no informed
consent from patients is needed. LP, CF and MR had the
full access to the prescription database.
As reported in the previous paper [12] the sample
population consisted of men ≥40 years who had been
prescribed medications for BPH-associated LUTS during
the index period (January1st 2004-December31st 2006).
Only ABs and 5ARIs were considered in the analysis
(ATC codes: G04CA and G04CB, respectively). During the
study period, the first prescription of a drug was considered
as “index date” for including a patient. Patient adherence to
therapy was estimated only for patients receiving treatment
for a minimum of 6 months during the index period. Two
different levels of exposure to drugs were set: at ≥ 6 months
and at ≥12 months. Patients on treatment for more than
12 months during the index period were followed-up for
4 years (median time). Patients who: a) stopped one of the
three regimens (AB monotherapy, 5ARI monotherapy or
CT) for at least 2 consecutive months during the first year
of treatment and at least 4 months/yearly during the
follow-up period, or b) switched regimen were considered
as “treatment discontinuation”.
Patients were followed until hospitalization or surgery
for BPH occurred or until their last follow-up. Patients
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were excluded when they were diagnosed with urethral
stricture, prostate cancer in the 12 months preceding
the index day.
Hospital admissions were recorded for patients receiv-
ing ≥1 year of pharmacological therapy and they were
considered “BPH-related” when hospital records in-
cluded a primary diagnosis and/or a surgical procedure
related to BPH.
The presence of the ICD9-CM 600.xx code as primary
diagnosis without surgical procedures was considered as
a “BPH-related hospitalization”. In the absence of clear
and universally agreed upon indications for BPH-related
hospitalization we included in the analyses all the hospi-
talizations for haematuria, urinary tract infection, urin-
ary retention, bladder stones, and renal failure due to
urinary tract obstruction caused by BPH.
The presence of ICD9-CM codes 57.0,57.91,57.92,60.21,
and 60.29,60.3,60.4 as primary or secondary surgical
procedures with any primary diagnoses was considered
hospitalization for “BPH-related surgery”.
Statistical analysis
For patients with at least 12 months of treatment, the
characteristics were reported using descriptive statistics.
Differences between patient treatment subgroups were
assessed using a standardized difference (SD). Crude in-
cidence rates (IRs) per 1000 men/year and incidence rate
ratios (IRRs) with 95 % confidence intervals (CIs) were
calculated with the Poisson regression model.
A multivariable Cox proportional hazards regression
model was used to account for differences in follow-up
and in baseline characteristics among groups. In all Cox
models, the associations between groups and all out-
comes were adjusted for co-variates known to be of
prognostic importance to the outcomes: age and previ-
ous hospitalization for BPH, history of BPH-related sur-
gery, and previous pharmacological treatment. Results
were expressed as hazard ratios (HRs) and 95 % CIs. Ad-
justed event-free survival curves were calculated using
the corrected group prognosis method. Discontinuation
rate according to treatment group was compare using
Pearson chi square test.
All reported that p-values are two tailed, and a p-value
less than 0.05 was considered statistically different.
Analyses were conducted using SAS Statistical Package
Release9.3 (SAS Institute, Cary, NC, USA).
Results
From the initial cohort of about 6.5 million individuals,
men ≥40 years old were 1,447,074. Among these, only
28,273 received prescriptions for 12 months for BPH-
associated LUTS, and this group was followed (median
follow up 4 years, IQR 2–5.3) and represented our
study cohort.
General characteristics of the group are summarized
in Table 1. ABs was the most frequently prescribed drug
class (87.1 %), followed by 5ARIs (8.1 %) and CT (4.7 %)
that was prescribed in older patients.
Drug adherence
Patients who received prescriptions for ≥6 months were
97,407, and decreased to 61298 (63 %) at 10 months and
to 28,273 (29 %) at 12 months. Patients who continued
taking their drugs for up to 12 months were 35 %, 18 %
and 9 % for ABs, 5ARIs and CT, respectively. These rates
decreased to 15 %, 8 % and 3 % at 60 months (Fig. 1).
In men who received drug prescription for at least
12 months, the 5-year adherence was 42 % (Fig. 1). Pa-
tients who remained under pharmacological therapy for
the entire follow-up period (median 4 years) represented
13 % of those identified in the index period.
Patients under CT showed a higher discontinuation
rate all along the follow-up (p < 0.0001) compared to
either monotherapy (Fig. 1).
During the follow-up period, only 12270 patients con-
tinued their prescribed pharmacological therapy. The
discontinuation rate was statistically significant higher in
patients under CT (discontinued vs adherent patients:
SD % 19.87) (Table 2).
Hospitalization rates
During the follow-up period, the hospitalization rates
for BPH and BPH-related surgery were 9.04 (95 % CI
8.49–9.62) per 1000 patient/year and 12.6 (95 % CI
11.96–13.28) per 1000 patient/year, respectively (Table 3).
As previously shown [12], the multivariate analysis
confirmed that the use of 5ARIs was associated with a
reduced risk of hospitalization due to BPH and BPH-
related surgery (HR 0.46, 95 % CI 0.33–0.65 and HR
0.23, 95 % CI 0.15–0.35; p < 0.0001).Drug discontinu-
ation on multivariate analysis was an independent risk
factor for either BPH-related hospitalization or BPH
surgery regardless of the therapeutic group (HR 1.65, 95 %
CI 1.43–1.89 and HR 2.80, 95 % CI 2.59–3.03; p < 0.0001),
as already reported [12].
Discussion
BPH represents a major public health issue because of
its increasing prevalence, progressive nature and treat-
ment costs [19–21]. Current guidelines recommend the
use of ABs and 5ARIs as monotherapy or in combin-
ation for the treatment of BPH-associated LUTS [5,6].
However, a gap exists between guidelines and actual
clinical practice [10,12, 21]. In “real life” the low adher-
ence to prescribed medications is a recognized problem
for chronic diseases [13]. Some studies deeply evaluated
the problems of drug prescription and adherence for
BPH as well as its impact on the clinical outcomes
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[12, 19, 21–23]. All showed concordant results: 1) the
reported adherence in clinical trials is higher than
that observed in real life; 2) the duration of treatment
for BPH-associated LUTS is extremely short; 3) the ad-
herence to treatment is generally low and 4) this might
negatively influence BPH-related hospitalization rates.
By and large, patient adherence, or compliance, to a
prescribed drug treatment is defined as the extent to
which a person's attitude in terms of taking medication
coincides with the medical or health advice he receives.
Adherence or compliance to a drug regimen is divided
to primary non-compliance, for example when one re-
ceives a prescription, but does not have it made up at a
pharmacy. Forms of secondary non-compliance include
taking incorrect doses of the prescribed medication, tak-
ing the medication at wrong times, forgetting one or
more doses of the medication, or altogether stopping the
medication, either by ceasing to take the medication
sooner than the doctor recommended or failing to ob-
tain a repeat prescription [24]. Poor adherence to a
therapeutic regimen has been identified as a major pub-
lic health problem that may have a major impact on
clinical outcomes [25].
The lack of a valid method for measuring compliance is
by itself a major barrier to compliance research. Both direct
and indirect measures have been sought in order to quan-
tify compliance, and although direct measures are consid-
ered to be the most accurate, their invasive nature makes
them unacceptable and inappropriate to use. Indirect mea-
surements are therefore more frequently reported in the lit-
erature and include measures such as interviews, diaries,
tablet counts, and prescription refill dates. Interviews and
Table 1 Patients’ characteristics in relation to BPH treatment.
Variable Baseline
Overall AB 5ARI CT % Standardized difference *
28273 24626 2309 1338 5ARI vs AB CT vs AB
No. (%) No. (%) No. (%) No. (%)
Mean age (± SD) 70.28 (9.46) 69.55 (9.36) 75.61 (8.72) 74.49 (8.25) 66.99 58.3
Age
40–55 1699 (6.01) 1641 (6.66) 42 (1.82) 16 (1.20) −24.22 −28.42
56–65 7001 (24.76) 6579 (26.72) 248 (10.74) 174 (13.00) −41.83 −34.89
66–75 11,120 (39.33) 9819 (39.87) 791 (34.26) 510 (38.12) −11.65 −3.6
76–85 7054 (24.95) 5555 (22.56) 961 (41.62) 538 (40.21) 41.71 38.75
>85 1399 (4.95) 1032 (4.19) 267 (11.56) 100 (7.47) 27.63 14.04
Previous hospitalization for BPH 1312 (4.64) 1048 (4.26) 167 (7.23) 97 (7.25) 12.82 12.88
Previous BPH surgery 98 (0.35) 88 (0.36) 7 (0.30) 3 (0.22) −0.94 −2.47
Previous BPH severity factors 854 (3.02) 715 (2.90) 95 (4.11) 44 (3.29) 6.58 2.22
Previous BPH related therapy 16,491 (58.33) 14,220 (57.74) 1377 (59.64) 894 (66.82) 3.84 18.8
Legend: AB: Alpha-blocker monotherapy; CT: Combination Therapy 5ARI; 5-alpha reductase inhibitors monotherapy; * Standardized difference greater than 10 %
represents meaningful imbalance in explored variable between treatment groups
Fig. 1 Differences in adherence between different pharmacological regimens at 1, 2, 3, 4 and 5 years of follow-up
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all self-report methods are vulnerable to overestimates of
compliance and underestimates of non-compliance [26].
There are inherent limitations with these methods for gen-
erating valid and reliable data to give an accurate estimate
of extent of patient adherence. Data from administrative
databases, used in our and in other studies, are another in-
direct but reliable method of estimating drug consumption
and patient adherence to a certain regimen [12, 21, 22].
Patient adherence to medical treatment is generally sub-
optimal irrespective of the drug or the treated condition.
Studies on patient adherence on pharmacological therapy
for the treatment of hypertension have shown that 50 % of
patients discontinue their medication while two-thirds of
patients that stay on treatment seem to lower their drug
doses [26].
Although data regarding pharmacotherapy for BPH-
associated LUTS are limited, a recent study from France
confirmed that the 1-year adherence ranges between
21 % to 26 [21]. Madershbacher in 2007, looking at the
results from clinical trials, depicted a clinical scenario
describing the adherence rates of different therapeutic
regimens. They found that the discontinuation rates in
the 5-ARIs trials were lower than in the AB trials; and
confirmed a 2-year discontinuation rate of 10–20 % of
patients under 5ARIs. On the other hand, discontinu-
ation rates were lower for combination therapy (18 %)
compared to finasteride (24 %) and doxazosin (27 %)
monotherapy [19]. Even more interesting, these data are
in contradiction with our results: a statistically signifi-
cant lower adherence for CT compared to either AB or
5ARI monotherapies. These discrepancies are probably
due to different study design. Our “real life” approach
shows that patients abandon CT for several reasons that
should be better investigated. Moreover, we found that
the prolonged use of 5ARIs and adherence to the
prescribed regimen were significantly associated with a
lower risk of BPH-related hospitalization and surgery.
In the BPH population the decision to adhere to
pharmacological treatment is primarily based on the pa-
tient’s perception of bother due to LUTS and its impact
on quality of life, and definitely depends on patient ex-
pectations and beliefs. The patient’s perspective towards
BPH and its management play a major role in the deci-
sion to initiate, continue or abandon treatment [27].
Even if we recognize that the reasons for the lack of
drug adherence are multiple and difficult to analyze
Table 2 Patients’ characteristics according to drug adherence
VARIABLE Discontinuated patients Adherent patients Standardized difference (%) *
Mean age (± SD) 70.15 (9.6) 70.37 (9.34) -
Age class
40–55 762 (6.21) 937 (5.86) −1.4916
56–65 3131 (25.52) 3870 (24.18) −3.0886
66–75 4784 (38.99) 6336 (39.59) 1.2350
76–85 2936 (23.93) 4118 (25.73) 4.1775
>85 657 (5.35) 742 (4.64) −3.2957
Previous hospitalization for BPH 560 (4.56) 752 (4.70) 0.6430
Previous BPH surgery 45 (0.37) 53 (0.33) −0.6030
Previous BPH severity factors 392 (3.19) 462 (2.89) −1.7928
Previous BPH related therapy 7155 (58.31) 9336 (58.34) 0.0529
Therapeutic regimen
AB 10923 (89.02) 13703 (85.63) −10.2158
5ARI 1050 (8.56) 1259 (7.87) −2.5140
CT 297 (2.42) 1041 (6.51) 19.8785
Legend: AB: Alpha-blocker monotherapy; 5ARI; 5-alpha reductase inhibitors monotherapy; CT: Combination Therapy; * Standardized difference greater than 10 %
represents meaningful imbalance in explored variable between treatment groups
Table 3 Hospitalization rates for BPH and BPH-related surgery
Outcomes Overall Mono alpha Mono 5ARI CT
Events IR (95 % CI) Events IR (95 % CI) Events IR (95 % CI) Events IR (95 % CI)


















Legend: AB: Alpha-blocker monotherapy; 5ARI; 5-alpha reductase inhibitors monotherapy; CT: Combination Therapy; IR: incidence rate for 1000 person-years
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(especially using this methodological approach), it is im-
portant to remember that the strategy “enhance compli-
ance by decreasing the number of pills” has been widely
demonstrated in other fields of medicine [14]. There is
convincing evidence from the literature suggesting that
adherence is inversely associated with the complexity of
the drug regimen. In this concept, the so-called fixed-
dose combination (FDC) drugs (2 or more drugs pro-
duced in a single pill/tablet) have been developed in
order to treat one disease with complementary actions
(e.g., diabetes mellitus, asthma) or treat multiple clinical
conditions (e.g., hypertension and hyperlipidemia) [14].
A FDC regime containing 0.5 mg of dutasteride and
0.4 mg of tamsulosin in the same pill is available for the
treatment of BPH-associated LUTS.
Recent reports show that the use of FDC is associated
with lifestyle advice resulted in rapid and sustained im-
provements in men with moderate BPH-associated
LUTS [28] and that FDC is a cost-effective option in a
estimated lifetime budget cost model [29] .
Even though the parameters that would modify patient’s
adherence are multiple and complex (spanning from
awareness campaigns to better patient counselling) it
seems reasonable to support the use of FDC for BPH-
associated LUTS in order to decrease patient withdrawal
and to increase adherence to the guidelines.
Several limitations of our study should be acknowl-
edged. Studies based on data from administrative data-
bases cannot be considered efficacy studies and do not
include clinical variables or patient reported outcomes
[30]. Another serious limitation is the imbalance be-
tween regimens, but this reflects the prescription atti-
tudes. Moreover the current analysis is specific to the
Italian situation and its generalization should be done
with caution.
In this study we demonstrated that in “real life” patient
adherence to BPH medication is different to that
reported in clinical trials and that patients under CT
abandon treatment more frequently that patients under
monotherapy do.
Conclusions
Patient adherence to pharmacotherapy for BPH-
associated LUTS is low. The need for combining two
drugs to treat BPH represents a serious obstacle to bet-
ter adherence. Persistence on pharmacological treatment
is associated with a lower rate of hospitalization for
BPH-related reasons. The use of a fixed-dose combin-
ation drug could increase adherence to treatment and
would likely prevent BPH progression.
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